Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria ...

Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline.

With UPLIZNA receiving a label expansion that opens the door to a previously untapped rare disease market, Amgen is seeing strong returns on ...

Sanofi has not had the success it was hoping for with its oral BTK inhibitors, acquired as part of its $3.7 billion buyout of Principia Biopharma, but can now point to a win for rilzabrutinib in ...

locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy [ID6482] Technology appraisal guidance Rilzabrutinib for treating persistent or chronic immune ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Researchers conducted a randomized clinical trail examining the effects of theta-burst stimulation on treatment resistant depression.

As of 2:38:16 pm GMT+7. Market open.

Aneurysms are a rare but possible manifestation of IgG4-RD. An elderly male patient with multiple aneurysms was eventually diagnosed with immunoglobulin G4-related disease (IgG4-RD) following ...

Researchers seek to better predict patients with PBC who may be unresponsive to UDCA treatment in order to switch to second-line therapies. Ursodeoxycholic acid (UDCA) remains the standard of care in ...